Equecabtagene Autoleucel

伊基奥仑赛

Report date: 2026/05/10 20:00:19

Base Information

Drug NameEquecabtagene Autoleucel
Drug Alias Name伊基仑赛Eque-cel依卡基奥仑赛福可苏FUCASO +[8] 
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived +[4] 
Mechanisms of ActionB-cell maturation protein inhibitors
TargetsB-cell maturation protein
Therapy Area/IndicationsMyelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseAutoimmune DiseasesLupus Erythematosus, Systemic +[15] 
Global Approved IndicationsMultiple Myeloma
Approved Indications in ChinaMultiple Myeloma
Original Approved Country/TerritoryMainland China
Original Approved Date2023/06/30
Country/TerritoryUnited StatesSingaporeMacau +[6] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesInnovent Biologics(Suzhou) Co LtdNanjing Iaso Biotherapeutics Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesShanghai Iaso Biotechnology Co LtdNanjing Xunlu Biomedicine Co LtdGC Cell Corp +[5] 
Inactive CompaniesInnovent Biologics(Suzhou) Co Ltd
Active IndicationsMyelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseAutoimmune DiseasesLupus Erythematosus, Systemic +[15] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A